

MEDICAL PHARMACIES NEW DRUGS

Drug Information and News for Health Care Providers


August 2016

DUAKLIR™ GENUAIR® (ACLIDINIUM BROMIDE/ FORMOTEROL FUMARATE)

Duaklir Genuair is an inhaled medication for the treatment of COPD (chronic obstructive pulmonary disease) that has recently received limited provincial formulary coverage. Duaklir Genuair contains a combination of a long-acting muscarinic antagonist (LAMA) with a long-acting beta₂-agonist (LABA) in a preloaded, multi-dose inhaler device.



- **Dosage:** A multi-dose dry powder inhaler in a dose of 400 mcg acclidinium/12 mcg formoterol, one inhalation twice daily.
- **Uses:** Duaklir Genuair is a long-term treatment for residents with COPD. It is taken regularly to control symptoms and prevent exacerbations of COPD. It should **not** be used as a “rescue medication” to treat acute exacerbations of COPD or for the management of asthma.
- Another combination product that is in the same class as Duaklir Genuair is Inspiolto™ Respiimat® (tiotropium/olodaterol).



Please refer to Duaklir™ Genuair® product monograph for more comprehensive information regarding inhalation technique, including warnings and precautions.

References:

- Duaklir™ Genuair® Product Monograph. AstraZeneca Canada Inc. April 2015.
- Aggarwal B, Gogtay J. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence. *Expert Rev Respir Med.* 2014;8(3):349–56.
- Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? *Age Ageing* 2007;36(2):213–8.
- Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management, and prevention. Updated 2015. Available online at http://www.goldcopd.it/materiale/2015/GOLD_Pocket_2015.pdf. Accessed June 30, 2016.